Hookipa Receives Additional Grant Support From FFG For Development Of Vaccine Candidate HB-101

Vienna Austria, April 22, 2014 - Hookipa Biotech AG, a biotech company pioneering a
new class of vaccines, today announced the award of a major grant from the Austrian
Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public
funding agency for translational research in Austria.

A EUR 3.38 million support is given for the second year of a multi-year vaccine development
project. The grant will be used to further progress the development of Hookipa´s lead
product candidate, HB101, a vaccine against cytomegalovirus (CMV) that is currently in
advanced pre-clinical testing.

“We have made a very significant progress with our CMV vaccine candidate, and we would
like to thank FFG for its continuous support of this important project”, commented Dr.
Katherine Cohen, CEO of Hookipa Biotech AG.

About Hookipa Biotech AG
Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic
vaccines based on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel
vaccine platform using a replication-defective viral vector for the prevention and treatment
of multiple infectious diseases and cancer. The platform is one of the most promising new
technologies for next generation vaccines due to its ability to stimulate both potent B-cell
and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models.
Unlike other vectors, Vaxwave® vaccines can be administered repeatedly to boost the
immune system. The Company is focused on the development of its lead vaccine candidate
HB101, a vaccine for immunization against cytomegalovirus (CMV) and plans to further
industrialize the Vaxwave® technology and build a robust product pipeline in the area of
infectious diseases and cancer. Hookipa has raised a total of € 27 million in equity finance
from internationally renowned venture capital investors including Sofinnova Partners,
Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and
BioMedPartners.

Contact:
Dr. Katherine Cohen
Chief Executive Officer
Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna, Austria
Email: office@hookipabiotech.com